Biotie Therapies - Major shareholder announcements

Notification according to Chapter 2, Section 10 of the Finnish Securities Market Act

BIOTIE THERAPIES CORP.    STOCK EXCHANGE RELEASE 3 February 2011 at 11.15 a.m.

Notification according to Chapter 2, Section 10 of the Finnish Securities Market
Act

Biotie Therapies Corp. ("Company" or "Biotie") has gained knowledge of the
notifications regarding changes in holdings in accordance with Chapter 2,
Section 9 of the Finnish Securities Markets Act, described below.

The notifications received by the Company concern the changes in holdings in the
Company of Versant Ventures III LLC (through Versant Venture Capital III LP and
Versant Side Fund III LP).

The mentioned parties are parties to a Combination Agreement entered into on 10
January 2011 among the Company, Synosia Therapeutics Holding AG ("Synosia") as
well as Synosia's shareholders and warrant holders, described in more detail in
a stock exchange release issued on 11 January 2011. As described in detail in
Biotie's stock exchange release issued on 2 February 2011, Biotie's
Extraordinary General Meeting has on 1 February 2011 passed resolutions
necessary for the completion of the transaction and the other prerequisites for
the completion of the transaction have been fulfilled, and the Company has
issued 161,448,371 shares to the shareholders and warrant holders of Synosia as
consideration for the entire issued share capital and outstanding warrants of
Synosia (the "Transaction"). In connection with the Transaction, the Company
issued 14,912,155 to Synosia to be held in treasury and used to satisfy future
potential exercise of Synosia's options. The new shares have been registered on
3 February 2011.

In the Transaction new shares in the Company were issued to the notifying
parties, and the resulting holdings of shares and votes in the Company of the
notifying parties after the completion of the Transaction are as follows:

Name            Number of shares   Voting rights      Share of      Share of
                to be received     shares to be       share capital voting
                subject to         received subject   (%)           rights (%)
                completion of      to completion of
                Transaction        Transaction

Versant Venture 34,067,104         34,067,104         9.67          10.56
Capital III LP
(Versant
Ventures III
LLC being its
partner)

Versant Side    201,237            201,237            0.06          0.06
Fund III LP
(Versant
Ventures III
LLC being its
partner)

Versant         34,268,341         34,268,341         9.73          10.62
Ventures III
LLC (through
Versant Venture
Capital III LP
and Versant
Side Fund III
LP) in total

The number of voting rights and percentages presented above are calculated based
on number of shares and voting rights obtained upon completion of the
Transaction taking into account the treasury shares held by the Company on the
date of the notification.

On the date hereof, the registered number of shares in Biotie Therapies Corp. is
352,364,457. Of these shares 29,659,239 are held by the Company or its group
companies and the number of outstanding registered shares and voting rights
attached to such shares amounts thus to 322,705,218.

Turku, 3 February 2011

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900
e-mail:virve.nurmi@biotie.com

DISTRIBUTION
NASDAQ OMX Helsinki Ltd
Main Media
www.biotie.com


[HUG#1484993]